From the Back Cover New technologies and tools to guide drugs through the discovery process Most drugs never leave the laboratory as a result of failure to predict efficacy and safety. In response, this book offers readers an array of new and emerging technologies. These technologies arm pharmaceutical scientists with more systematic and effective approaches for deciphering the complex interactions among chemistry, biology, and medicine, helping to ensure that more research efforts focus on drugs that can be successfully translated from the laboratory to the clinic and onto the market. Among the topics addressed in Drug Efficacy, Safety, and Biologics Discovery are: High throughput protein-based technologies and computational models for drug development, efficacy, toxicity, systems pharmacology, biomarkers, biomolecular networks, computational systems biology modeling of dosimetry, cellular response pathways, nanotechnology to improve drug delivery, and modeling efficacy and safety of engineered biologics Each of the fourteen chapters has been authored by one or more of the leading experts in the field. Their advice is not only based on a thorough review of the latest findings, but also their own firsthand experience in drug discovery and development. Extensive references guide readers to the literature for more in-depth investigations of particular topics. By cutting across the many disciplines needed for successful drug discovery, this book suits the needs of all chemists, biologists, and technologists involved in drug discovery and development. Moreover, by advocating for cross-disciplinary collaboration, this book is certain to fuel future innovation in drug discovery. Read more About the Author Sean Ekins, MSc, PHD, DSc, is the Principal at Collaborations in Chemistry; and Adjunct Associate Professor in the Department of Pharmaceutical Sciences at the University of Maryland, School of Pharmacy. Dr. Ekins has published widely on ADME/Tox, systems biology, computational, and in vitro drug discovery approaches. He has previously edited two Wiley books: Computer Applications in Pharmaceutical Research and Development (2006) and Computational Toxicology: Risk Assessment for Pharmaceutical and Environmental Chemicals (2007). Jinghai J. Xu, PHD, is Director of Automated Biotechnology at Merck. Previously he headed predictive toxicology at Pfizer, where he led research activities in drug-induced liver injury, genetic toxicology, drug transporters, assay development, high content screening, in vitro in vivo correlations, systems biology, and systems toxicology. Dr. Xu has served on steering committees of academic-industry and industry-industry collaborations, and as a guest lecturer at the Massachusetts Institute of Technology. Read more
Trustpilot
1 week ago
1 week ago
